PharmaShots Weekly Snapshots (August 8 - 12, 2022)
Pfizer Reports Results of 20vPnC in P-III Trial for the Prevention of Invasive Pneumococcal Disease
Published: Aug 12, 2022 | Tags: Pfizer, 20vPnC, Invasive Pneumococcal Disease, Clinical Trial, P-III
Published: Aug 12, 2022 | Tags: Daiichi Sankyo, AstraZeneca, Enhertu, HER2 Mutant Metastatic Non-Small Cell Lung Cancer, Regulatory, US, FDA, P-II, DESTINY-Lung02
Argenx’s Vyvgart Receives the EC’s Approval for the Treatment of Generalized Myasthenia Gravis
Published: Aug 12, 2022 | Tags: Argenx, Vyvgart, Generalized Myasthenia Gravis, Regulatory, EU, US, FDA, Japan, China, Canada, P-III, ADAPT
Published: Aug 12, 2022 | Tags: BridgeBio, Sentynl, Medison, Nulibry, Molybdenum Cofactor Deficiency Type A, Regulatory, US, FDA, EMA, CHMP
Published: Aug 12, 2022 | Tags: Abbott, i-STAT TBI Plasma Test, Brain Injury, Clinical Trial, US, FDA, Alinity I, ARCHITECT
Published: Aug 12, 2022 | Tags: BMS, GentiBio, Treg Platform, Inflammatory Bowel Diseases, Pharma, Immunology, Autoimmune Diseases
Published: Aug 10, 2022 | Tags: Gamida Cell, GDA-201, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Clinical Trials
Published: Aug 10, 2022 | Tags: Just-Evotec Biologics, Alpine Immune Sciences, ALPN-303, J.DESIGN, Systemic Lupus Erythematosus, Inflammatory Disease, Autoimmune Diseases, Pharma, P-I & P-II
Published: Aug 10, 2022 | Tags: Innovent, Picankibart, IBI112, Plaque Psoriasis, Clinical trials, P-II, CIBI112A201 Study
Published: Aug 10, 2022 | Tags: AstraZeneca, Daiichi Sankyo, Datopotamab deruxtecan, Dato-DXd, Advanced NSCLC, P-Ib TROPION-Lung02 Trial, WCLC, 2022
Published: Aug 10, 2022 | Tags: Merck, Cerevance, Novel Targets, Alzheimer’s Disease, Pharma
GSK Entered into an Option Agreement with Mersana to Co-Development and Commercialize XMT-2056 for the Treatment of Cancer
Published: Aug 10, 2022 | Tags: GSK, Mersana, XMT-2056, Cancer, HER2-expressing tumors, Pharma
Published: Aug 8, 2022 | Tags: Eli Lilly, Taltz, ixekizumab, Citrate-Free Formulation, Injection Site Pain, Regulatory
Published: Aug 8, 2022 | Tags: HUTCHMED, AstraZeneca, Tagrisso, Savolitinib, EGFR-Mutated NSCLC, P-II SAVANNAH Trial
HUTCHMED Reports P-III (FRESCO-2) Trial Results of Fruquintinib for the Treatment of Metastatic Colorectal Cancer
Published: Aug 8, 2022 | Tags: HUTCHMED, Fruquintinib, Metastatic Colorectal Cancer, P-III, FRESCO-2 Trial
Published: Aug 8, 2022 | Tags: AstraZeneca, Daiichi Sankyo, Enhertu, trastuzumab deruxtecan, HER2-low Metastatic Breast Cancer, Regulatory, US, FDA, Approval
Published: Aug 8, 2022 | Tags: Genmab, BioNTech, Novel Immunotherapy, GEN1053, GEN1046, Cancer, HexaBody technology, Biotech
Published: Aug 8, 2022 | Tags: Myovant Sciences, Pfizer, Myfembree, Pain, Endometriosis, Regulatory, US, FDA, Approval
Related Post: PharmaShots Weekly Snapshots (August 1 – 5, 2022)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.